Texas seeks to block Kenvue dividend amid Tylenol lawsuit

Texas Attorney General Ken Paxton is seeking to block Kenvue (KVUE.N) from paying a nearly $400 million shareholder dividend, alleging the company concealed risks of Tylenol use during pregnancy and faces billions in potential damages from this and existing talc litigation. Paxton argues the dividend would be a fraudulent transfer, a claim Kenvue vehemently denies, calling the allegations "reckless and scientifically unsound." This legal action significantly complicates Kimberly-Clark's (KMB.O) recently announced $40 billion acquisition of Kenvue, with investor skepticism regarding the deal's viability and the financial impact of the litigation already evident in both companies' share performance.

Analysis

Texas Attorney General Ken Paxton has initiated legal action against Kenvue (KVUE) and its former parent Johnson & Johnson (JNJ), seeking to block Kenvue's scheduled $398 million shareholder dividend. Paxton alleges Kenvue concealed Tylenol risks to pregnant women, claiming the dividend would constitute a fraudulent transfer given potential multi-billion dollar liabilities from both Tylenol and existing talc litigation. Kenvue vehemently denies these allegations, labeling them "reckless and scientifically unsound," and plans to pursue immediate legal action against Texas.

This lawsuit significantly complicates Kimberly-Clark's (KMB) recently announced $40 billion acquisition of Kenvue. The market has reacted negatively, with Kimberly-Clark shares declining nearly 15% following the merger announcement, reflecting concerns over the protracted and expensive nature of the Tylenol litigation. Kenvue shares closed approximately 23% below the takeover price, signaling investor doubt regarding the merger's completion under original terms.

The litigation introduces substantial uncertainty regarding Kenvue's financial outlook and capital allocation, particularly concerning its ability to return capital to shareholders. While medical societies generally consider Tylenol safe for pregnancy, the political motivations behind the lawsuit, including Paxton's U.S. Senate bid and the suit's filing in a Trump-heavy county, add a layer of complexity to the legal proceedings.

Key Decisions for Investors

• Closely monitor the legal proceedings initiated by the Texas AG against Kenvue, as the injunction request and potential multi-billion dollar liabilities could significantly impact the Kimberly-Clark acquisition's terms or viability
• Evaluate Kenvue's and J&J's long-term litigation exposure from both Tylenol and talc cases, considering the potential for substantial financial penalties and their effect on future cash flow and valuation
• Consider the political motivations behind the lawsuit, which may introduce additional volatility and uncertainty into the legal process, potentially prolonging resolution